Gerresheimer surprises with strong sales growth despite market developments

Gerresheimer surprises with strong sales growth despite market developments

Laimgrubengasse 10, 1060 Wien, Österreich - Gerresheimer AG achieved impressive results in the financial year 2024 despite challenging market conditions. The turnover amounted to 2,035.9 million euros, which corresponds to an increase compared to 1,990.5 million euros in 2023. Adjusted Ebitda also increased to 419.4 million euros, compared to 404.5 million euros in the previous year, such as ots.at . The company recorded organic sales growth of 2.9 % and an improvement in the EBITDA margin to 20.6 %.

The growth in the Plastics & Devices division was particularly outstanding, which increased by 8.0 % and now shows sales of EUR 1,141.3 million. This positive development was promoted by the increasing demand for medication tax systems and tailor -made solutions. In contrast, the Primary Packaging Glass division suffered from the ongoing inventory effects, which had a negative impact on the revenue that was 898.6 million euros, such as glassonline.com . The integration of the recently acquired Bormioli Pharma should make significant sales contributions in the coming financial year.

growth forecasts under adjustments

In terms of business prospects, Gerresheimer has changed its growth forecast for 2024. Organic growth of 5 to 10 % was originally expected, now the company only expects 3 to 4 %. The adaptation is partly a reaction to the market recovery and the effects of the flood disaster in the Morganton plant, which had to be exposed to production for several weeks. Despite these challenges, the company remains optimistic and plans to achieve profitable growth through strategic changes, such as the focus on biopharmaceutical products.